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Chemoprevention by endocrine factors
The protective effect of pregnancy with respect to breast
cancer was documented by Ramazzini over 300 years
ago, who noted the higher rates of breast cancer among
Catholic nuns. Epidemiological studies have shown that a
single full-term pregnancy reduces risk of breast cancer by
~50% [1]. Carcinogen exposures at various times during
development of the mammary gland have shown that risk
of breast cancer is not static but varies among develop-
mental states [2–4]. The mature nulliparous mammary
gland is relatively quiescent with respect to proliferation,
but represents a susceptible state. Although p53 protein
is expressed in the quiescent mammary epithelium of nulli-
parous mice, responses to γ-radiation (cell-cycle arrest
and apoptosis) were marginal until activated by acute
administration of a hormonal regimen mimicking the rise in
ovarian steroids that precedes ovulation [5]. In contrast,
the proliferation and differentiation associated with preg-
nancy renders the mammary epithelium resistant to devel-
opment of tumors [4,6].
Sivaraman et al. [7] report a sustained activation of p53
function in the mammary epithelium of rats and mice fol-
lowing treatment with a regimen of estrogen and proges-
terone (E + P) that was effective in inhibiting mammary
tumors. In this experiment, postpubertal rats and mice
were treated with E + P for 21 days to induce mammary
gland development that mimics the changes associated
with pregnancy. The hormones were withdrawn to simu-
late involution of the mammary gland prior to administra-
tion of carcinogen.
Accumulation of nuclear p53 protein was detectable after
carcinogen treatment in E + P-treated animals, but not in
age-matched virgins. Expression of p21/WAF1, which is
induced rapidly by p53, was used to assess p53 activity in
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Improvements in the detection and treatment of breast cancer have dramatically altered its clinical
course and outcome. However, prevention of breast cancer remains an elusive goal. Parity, age of
menarche, and age at menopause are major risk factors drawing attention to the important role of the
endocrine system in determining the risk of breast cancer, while heritable breast cancer susceptibility
syndromes have implicated tumor suppressor genes as important targets. Recent work demonstrating
hormonal modulation of the p53 tumor suppressor pathway draws together these established
determinants of risk to provide a model of developmental susceptibility to breast cancer. In this model,
the mammary epithelium is rendered susceptible due to impaired p53 activity during specific periods of
mammary gland development, but specific endocrine stimuli serve to activate p53 function and to
mitigate this risk. The results focus attention on p53 as a molecular target for therapies to reduce the
risk of breast cancer.
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the mammary gland [5,8]. Accordingly, elevated levels of
p21/WAF1 protein were detected within the mammary
epithelium of E + P-treated animals, supporting a func-
tional p53 response to carcinogen treatment. This is con-
sistent with the decrease in proliferation observed in the
E + P-treated rats in response to carcinogen treatment
[7]. Perphenazine treatment, which induces secretion of
prolactin, causing differentiation of the mammary gland but
not resistance to tumors [9], failed to activate p53 in this
experiment. Differentiation alone is therefore unable to
activate p53 or to account for the prophylactic effects of
E + P treatment on the mammary epithelium.
These experiments of Sivaraman et al. [7] suggest that
prophylaxis is mediated by specific hormone receptor
pathways (estrogen and progesterone receptors) and that
they strengthen the association between p53 activation
and chemoprevention.
Reconciling the conflicting effects of
endocrine factors
A model of hormone-mediated prophylaxis must also
account for the roles of endocrine factors in promoting
breast cancer. Estrogen plays an important role in normal
proliferation of the mammary epithelium and participates in
progression to a neoplastic state. Selective estrogen
receptor modifiers offer great promise for chemopreven-
tion [10,11], incriminating estrogen as a primary suspect
in breast cancer. However, progesterone and prolactin
may act as accomplices, enhancing tumor development
[12,13]. Pituitary isografts induce hormone profiles similar
to midpregnancy, but result in hyperplasia and increased
incidence of mammary tumors [14,15]. The dramatic
reduction in risk of breast cancer in women who have
undergone ovariectomy serves to confirm the influential
role of ovarian steroids in promoting breast cancer [16].
From this perspective, hormonal stimulation is the cause
of breast cancer, not the cure!
So how can ovarian steroids mediate both susceptibility to
breast cancer and prophylaxis? In the report by Sivaraman
et al. [7], the authors propose a cell-fate model in which
pregnancy hormones restrict the developmental fate of a
subset of mammary epithelial cells causing permanent
changes in their responses to carcinogen stress, and
therefore making them resistant to tumorigenesis.
However, prolonged endocrine stimulation can overcome
the prophylactic effect of pregnancy [17]. Models must
therefore accommodate the reversibility of hormone-
mediated resistance to mammary tumors.
Alternatively, hormonal exposure may alter the sensitivity of
the mammary epithelium to hormonal stimuli. In support of
this notion, the parous mammary gland was shown to be
more responsive to hormonal induction of lactose syn-
thetase activity without alteration of either the affinity or
the capacity of estrogen receptors [18,19]. Changes in
hormonal sensitivity may reflect alterations in the balance
of coregulatory molecules. Like lactose synthetase, persis-
tent activation of p53 in the parous mammary epithelium
may result from an alteration in sensitivity rather than a
permanent change in cell fate.
The cell-fate model also poses difficulties with respect to
development of the mammary gland in subsequent preg-
nancies. Persistent activation of p53 in the parous
mammary gland would appear to limit proliferation as well
as to inhibit tumor formation. This is clearly not the case.
The inhibitory effects of p53 must therefore be overcome
to allow growth and differentiation of the mammary epithe-
lium in subsequent pregnancies. This too is consistent
with the fact that hormone-mediated prophylaxis is also
reversible [17].
The model of p53-mediated prophylaxis induced by hor-
monal stimulation is attractive given the role of p53 as a
potent inhibitor of cellular proliferation and an inducer of
apoptosis. However, a quantitative measure of the effects
of the E + P treatments on p53 activity was not under-
taken in the report by Sivaraman et al. [7]. Demonstration
that the protective effect of E + P is abolished in p53-defi-
cient mammary tissue will be required for final proof of this
concept. Nonetheless, identification of the hormones
required to activate p53 and the endocrine balance nec-
essary to overcome the limits imposed by p53 in the
parous gland will offer insights into important signaling
pathways and effector genes that regulate p53 activity.
Regulators of p53 as targets of
chemoprevention
Expression of p53 mRNA showed dramatic changes
across periods of mammary gland development [8], but no
direct effect of hormones on levels of p53 mRNA has
been established [6]. Nonetheless, alterations in p53
activity were apparent following endocrine manipulations
[5]. The effects of hormones on p53 activity may be medi-
ated by interactions with antagonists (e.g. MDM2, MDMX)
and agonists (e.g. p19/ARF) of p53 that attenuate or
augment its activity.
Post-translational modification has also emerged as a
potent means to balance latent and active forms of p53
protein. Recent accounts reveal multiple covalent modifi-
cations of p53 protein (phosphorylation, acetylation, ribo-
sylation, sumoylation) that alter its stability and its
subcellular localization, as well as affecting its ability to
bind DNA and transcriptionally activate target genes [20].
The host of enzymes that catalyze these reactions pro-
vides a rich set of targets on which endocrine factors may
impinge to regulate p53 function (Fig. 1). These enzymatic
activities also provide targets for development of small
molecules to alter the activity of p53 protein.Susceptibility, genetics and environment
Susceptibility to breast cancer is determined not only by
environmental factors, such as reproductive history, but
also by genetic factors. Again, p53 appears to play a
central role in heritable breast cancer susceptibility syn-
dromes. Li–Fraumeni syndrome is associated with hetero-
zygous germline mutations in the gene encoding the p53
protein (TP53). Although families harboring heterozygous
mutations in TP53 suffer from a wide spectrum of tumors,
breast cancer is the most prevalent tumor type in women,
suggesting a critical role for p53 in the breast epithelium.
Heritable mutations in BRCA1 also result in a sensitivity to
breast cancer that is accompanied by instability and fre-
quent loss of TP53 [21,22], again implicating disruption of
p53 function as a seminal event in breast tumorigenesis.
The absence of male breast cancer in both Li–Fraumeni
syndrome and BRCA1 families and the effective reduction
in breast cancer risk by endocrine ablation in carriers of
BRCA1 [23] suggest an interaction between the
endocrine environment and these susceptibility genes.
Therefore, factors that affect either the integrity of the TP53
gene or its activity may serve to modify the risk (Fig. 2).
The phenotypic variation among women who are carriers
of known breast cancer susceptibility alleles suggests the
presence of low-penetrance genetic modifiers. These low-
penetrance modifiers may play significant roles in what is
presently termed ‘sporadic’ breast cancer, as well as in
the nearly 20% of heritable breast cancer that cannot be
accounted for by the known high-penetrance breast
cancer susceptibility genes [24]. The genes that modify
p53 function provide attractive candidates for low-
penetrance modifiers as well as targets for hormonal
modulation to augment or to diminish risk [25]. In this
view, p53 may serve to integrate the effects of genetic
susceptibility and environmental exposures to determine
risk (Fig. 2).
Era of hope
As the molecular details determining susceptibility of the
breast epithelium emerge, they will foster new enthusiasm
for chemoprevention. Elucidation of critical pathways will
make it possible to more accurately identify individuals at
risk and to tailor interventions. These pathways will also
provide markers that can be evaluated at intermediate time
points to accelerate testing of new agents for efficacy. The
experiments reported by Sivaraman et al. suggest that
p53 activity may provide one such marker. The enzymes
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Figure 2
Pathways affecting the risk of breast cancer. The prophylactic effect of
pregnancy hormones appears to act directly on the p53 protein to alter
its activity. Genetic susceptibility mediated by high-penetrance cancer
susceptibility genes appears to affect the integrity of the p53 gene,
whereas low-penetrance modifiers may serve to alter the activity of the
p53 protein. The kinases and acetylases that regulate p53 activity
provide targets for chemopreventive agents. 
Figure 1
Post-translational modifications that alter activity of the p53 protein. Enzymes that have been shown to modify specific amino acid residues of p53
are shown. Enzymes that inhibit the covalent modifications are indicated in red. P, phosphorylation; R, ribosylation; Ac, acetylation.that activate p53 by altering its post-translational modifica-
tions provide targets for novel chemopreventive agents.
Small molecules stabilizing the active conformation of p53
are an alternative to prophylactic hormonal treatments that
have already shown promise [26]. Although the complex
interplay between hormones and heritable risk will con-
tinue to pose challenges, the emerging pathways renew
hope for interventions aimed at preventing breast cancer.
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